An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study
Richards D. et al, (2022), Orphanet journal of rare diseases, 17
In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.
Drennan PG. et al, (2022), Clin transl sci
In vivo human keyhole limpet haemocyanin challenge in early phase drug development: A systematic review
Drennan P. et al, (2022), Clinical and translational science
Predictive validity in drug discovery: what it is, why it matters and how to improve it
RICHARDS D., (2022), Nature reviews drug discovery
Corrigendum to 'Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes' [Surgery 171 (2021) 77-87].
Shariq OA. et al, (2022), Surgery
COVID-19 therapeutics: challenges and directions for the future
Robinson PC. et al, (2022), Proceedings of the national academy of sciences
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial.
Dorward J. et al, (2022), Br j gen pract
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
Wechalekar A. et al, (2022), Bmc cardiovasc disord, 22
Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
PRINCIPLE Trial Collaborative Group None. et al, (2022)
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Fisher BA. et al, (2021), The lancet respiratory medicine
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults.
Veenith T. et al, (2021), Bmj open, 11
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Yu L-M. et al, (2021), Lancet
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.
Hinks TSC. et al, (2021), Lancet respir med
Multiple Endocrine Neoplasia Type 1 in Children and Adolescents: Clinical Features and Treatment Outcomes
SHARIQ O. and RICHARDS D., (2021), Surgery
A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial
Hinks TSC. et al, (2021), Ssrn electronic journal